The economic consequences of obesity are becoming impossible to ignore. According to research from the University of York presented at the International Congress on Obesity in Mexico City from 15 to 17 July 2026, the condition has pushed more than 600,000 working-age Britons out of the labour market. Analysing data from over 280,000 UK Biobank participants, economists discovered that people living with obesity were roughly four percentage points less likely to be in employment than their healthy-weight counterparts.
As lead author Aharon Katz has rightly stressed, tackling obesity would improve both public health and economic productivity, particularly as it affects people during their prime working years, making greater awareness, inclusion and targeted action essential. Yet rather than adopt the preventive, root-cause approach being pursued by the UK government, many governments facing similar obesity crises have instead made ultra-processed foods (UPFs) the central focus of the debate.
With the EU and EU at the forefront of an emerging regulatory wave on UPFs, policymakers must adopt a nuanced, multifaceted approach to rising obesity, whose complexity is becoming ever clearer through the latest research. Moving forward, they should look to the UK’s more balanced example, avoiding ill-founded, incoherent regulation in favour of positive nutrition policies tailored to individual needs and the true nature of obesity.
A growing and misunderstood challenge
The York findings form part of a much larger economic warning. Indeed, an assessment by Frontier Economics for Nesta last year valued Britain’s annual productivity losses from overweight and obesity at around £31 billion, with broader social and economic costs reaching £126 billion. Meanwhile, long-term illness is removing more people from the workforce, with economic inactivity among working-age Britons rising to 2.78 million in March 2026, compared with 2.05 million in 2019.
Yet Britain is hardly an outlier. Across the WHO European Region, 59% of adults were overweight or living with obesity in 2022, after prevalence had tripled in many countries since the 1980s. The WHO described the situation as having reached “epidemic proportions,” associating obesity and overweight with over 1.2 million deaths annually. Concerningly, by 2025, no European country was on track to reverse the trend, with the UK among the worst affected.
Obesity’s consequences extend far beyond body weight. Greater exposure to type 2 diabetes, cardiovascular disease, musculoskeletal conditions and certain cancers can damage health, shorten working lives and place added pressure on public services, making it one of the most urgent public health challenges of our time. Yet the condition remains difficult to treat precisely, with clinicians still unable to reliably predict who will develop serious complications or respond best to a given intervention, underscoring the need for policy grounded in complexity rather than outdated assumptions.
Against that backdrop, the SOPHIA project was created to bring greater precision to obesity care, which has long been shaped by BMI as a basic weight-to-height measure. Funded by the Innovative Medicines Initiative and European Commission, the public-private partnership examined the limits of BMI, which may help track population trends but cannot explain why people of similar weight face different risks or respond differently to treatment.. As project coordinator Carel le Roux notes, “earlier approaches to obesity management viewed all people with obesity as being the same,” with SOPHIA’s findings instead pointing towards more personalised care.
Anti-UPF revolution missing the mark
Despite these findings, governments around the world are racing towards sweeping rules on UPFs. In Washington, the FDA and USDA are developing a federal definition that could shape labelling, procurement and wider nutrition policy under Robert F. Kennedy Jr’s MAHA agenda. Across the Atlantic, the EU’s ‘Safe Hearts Plan’ places UPFs firmly on Brussels’ radar, including possible fiscal measures, even as the science remains unsettled.
This UPF regulatory wave reveals a deep regulatory incoherence. For years, food policy has judged products primarily through nutritional composition, with rules and labels centred on sugar, salt, fat and calories. Now, despite continuing uncertainty over whether processing level independently predicts health outcomes, policymakers are moving the goalposts, layering on a second and potentially conflicting standard that leaves manufacturers to operate, as food journalist Gill Hyslop has aptly noted, “under two regulatory philosophies at the same time” and consumers to navigate mixed signals.
More fundamentally, processing level is a shaky proxy for nutritional value. Researchers at the USDA’s Grand Forks Human Nutrition Research Center constructed a menu meeting federal dietary guidance even though NOVA classified 91 per cent of its calories as UPFs. Meanwhile, a 2024 USDA systematic review found generally small effects, frequent statistically insignificant results and no direct comparisons between equivalent foods in ultra-processed and non-ultra-processed forms. Such uncertainty makes processing alone too fragile a basis for broadbrush UPF regulation.
Encouragingly, the UK has chosen a more measured course. Rather than recast dietary guidance or regulation around NOVA alone, it continues to anchor public advice in overall diet quality while the Scientific Advisory Committee on Nutrition (SACN), which advises the UK government, assesses the evidence and its limitations. Crucially, this caution is not complacency, but instead creates much-needed room for policies centred on prevention, education, healthier environments and more personalised support.
Towards personalised anti-obesity interventions
Building on that more balanced foundation, more credible obesity strategies should help people build healthier lives rather than narrowing the debate to a single category of food. Stronger nutrition education in schools, practical guidance in workplaces and better access to affordable, varied diets can shape habits before poor health becomes entrenched. Effective policy must also account for the wider pressures that influence everyday choices, from income and time constraints to stress and the availability of healthy options locally.
At the same time, obesity does not follow a single clinical pathway. A person facing insulin resistance, sleep apnoea or mobility problems may need very different support from someone whose weight is shaped by medication, chronic stress or financial pressure. Earlier risk screening, multidisciplinary care linking GPs, dietitians, psychologists and specialists, and treatment adjusted over time would replace generic advice with support people can sustain. Combined with measures that reduce stigma and create healthier local environments, such support would give obesity policy the reach and precision it currently lacks.
Ultimately, if governments are serious about reducing obesity, they must look beyond any single product category and address the wider conditions that shape health, work and daily choices. That means sustained investment in prevention, education, personalised support and healthier environments, guided by evidence rather than political convenience. Only a comprehensive approach can protect individual wellbeing, strengthen economic participation and deliver lasting progress against a challenge of this scale.
Leave a Reply